Predicted 10-year CVD risk
1 paper1 finding
- Human trial1
Interventions
1Tirzepatide
downin humans1HR 0.62
1 study
Tirzepatide
downin humans1HR 0.62
Tirzepatide decreases predicted 10-year CVD risk in humans (HR = 0.62, ARR -1.31% vs ARI 3.84%, p < 0.001).
Human trialin individuals with obesity/overweight and prediabetes176 weeks
European journal of preventive cardiology10 Aug 2026
Latest
6 in 12 monthsBMC Cardiovascular Disorders
Association between the triglyceride-glucose-body mass index and the risk of early vascular aging in young and middle-aged Chinese adults: a cross-sectional study
Cross-sectional study of 1,272 peopleTriglyceride-glucose body mass index
European Journal of Preventive Cardiology
Predicted 10-Year Cardiovascular Disease Risk Reduction with Tirzepatide Use Over Three Years for Primary Prevention of Cardiovascular Disease in Obesity
Randomised trial in 2,539 peopleTirzepatide
AHA Scientific Sessions 2025 Abstract
Acculturation and Cardiovascular-Kidney-Metabolic Syndrome: a Study of Immigrant Adults From the National Health and Nutrition Examination Survey
Study in peoplePopulations
AHA Scientific Sessions 2025 Abstract
Reducing Carbohydrate Quantity Lowers 10-Year Predicted Risk of Cardiovascular Disease Using the PREVENT Equation: An Ancillary Study of the OMNICARB Trial
Trial in peopleInterventions
AHA Scientific Sessions 2025 Abstract
Association Between Social Determinants of Health and Cardiovascular-Kidney-Metabolic Syndrome in U.S. Adults From the National Health and Nutrition Examination Survey
Study in peoplePopulations